{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:46:25Z","timestamp":1772207185087,"version":"3.50.1"},"reference-count":79,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0227524","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T13:30:30Z","timestamp":1582723830000},"page":"e0227524","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["A C-terminal peptide from type I interferon protects the retina in a mouse model of autoimmune uveitis"],"prefix":"10.1371","volume":"15","author":[{"given":"Chulbul M.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristhian J.","family":"Ildefonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-9727","authenticated-orcid":true,"given":"Alfred S.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"issue":"5","key":"pone.0227524.ref001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the worldwide epidemiology of uveitis","volume":"23","author":"E Miserocchi","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"pone.0227524.ref002","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4939-8938-6_15","article-title":"Clinical and Functional Evaluation of Ocular Inflammatory Disease Using the Model of Experimental Autoimmune Uveitis","volume":"1899","author":"J Chen","year":"2019","journal-title":"Methods Mol Biol"},{"key":"pone.0227524.ref003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-1-60761-720-4_22","article-title":"Rodent models of experimental autoimmune uveitis","volume":"900","author":"RK Agarwal","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"1","key":"pone.0227524.ref004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11882-013-0409-1","article-title":"Noninfectious immune-mediated uveitis and ocular inflammation","volume":"14","author":"J Pan","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"pone.0227524.ref005","article-title":"Treatment of Neuro-Ophthalmic Sarcoidosis","author":"LP Frohman","year":"2014","journal-title":"J Neuroophthalmol"},{"key":"pone.0227524.ref006","first-page":"653539","article-title":"Immunopathogenesis of ocular Beh\u00e7et's disease","volume":"2014","author":"UC Park","year":"2014","journal-title":"J Immunol Res"},{"issue":"11","key":"pone.0227524.ref007","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.autrev.2013.01.004","article-title":"Vogt-Koyanagi-Harada syndrome","volume":"12","author":"A Greco","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"pone.0227524.ref008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2012.01.016","article-title":"Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease","volume":"154","author":"J Abbasian","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"pone.0227524.ref009","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1167\/iovs.13-13444","article-title":"Correlation between disease severity and presence of ocular autoantibodies in juvenile idiopathic arthritis-associated uveitis","volume":"55","author":"K Walscheid","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"pone.0227524.ref010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1352458514539782","article-title":"Uveitis as a prognostic factor in multiple sclerosis","volume":"21","author":"E Shugaiv","year":"2015","journal-title":"Mult Scler"},{"issue":"2","key":"pone.0227524.ref011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/bjophthalmol-2014-305518","article-title":"Characterisation of uveitis in association with multiple sclerosis","volume":"99","author":"W Messenger","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"pone.0227524.ref012","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.it.2015.04.003","article-title":"Immune mechanisms in inflammatory and degenerative eye disease","volume":"36","author":"VL Perez","year":"2015","journal-title":"Trends Immunol"},{"issue":"1","key":"pone.0227524.ref013","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/08830185.2012.747524","article-title":"Uveitis in mouse and man","volume":"32","author":"JV Forrester","year":"2013","journal-title":"Int Rev Immunol"},{"key":"pone.0227524.ref014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2013.06.003","article-title":"Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen","volume":"44","author":"R Horai","year":"2013","journal-title":"J Autoimmun"},{"key":"pone.0227524.ref015","doi-asserted-by":"crossref","first-page":"5065703","DOI":"10.1155\/2016\/5065703","article-title":"The Microbiota Determines Susceptibility to Experimental Autoimmune Uveoretinitis","volume":"2016","author":"J Heissigerova","year":"2016","journal-title":"J Immunol Res"},{"key":"pone.0227524.ref016","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fimmu.2019.00232","article-title":"Microbiome and Autoimmune Uveitis","volume":"10","author":"R Horai","year":"2019","journal-title":"Front Immunol"},{"key":"pone.0227524.ref017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/978-3-319-75402-4_53","article-title":"The Role of Microbiota in Retinal Disease","volume":"1074","author":"S Rowan","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"pone.0227524.ref018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14712598.2019.1595578","article-title":"Expert opinion on the use of biological therapy in non-infectious uveitis","volume":"19","author":"S Touhami","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"pone.0227524.ref019","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000336338","article-title":"New treatment options for noninfectious uveitis","volume":"51","author":"M Gomes Bittencourt","year":"2012","journal-title":"Dev Ophthalmol"},{"issue":"7","key":"pone.0227524.ref020","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1517\/14656561003713534","article-title":"Pharmacotherapy of uveitis","volume":"11","author":"FF Lee","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"416","key":"pone.0227524.ref021","doi-asserted-by":"crossref","first-page":"pe70","DOI":"10.1126\/stke.4162007pe70","article-title":"Type I interferons as anti-inflammatory mediators","volume":"2007","author":"EN Benveniste","year":"2007","journal-title":"Sci STKE"},{"issue":"2","key":"pone.0227524.ref022","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation","volume":"34","author":"G Guarda","year":"2011","journal-title":"Immunity"},{"issue":"2","key":"pone.0227524.ref023","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"JM Gonz\u00e1lez-Navajas","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"pone.0227524.ref024","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14712598.2018.1462793","article-title":"Recent developments in interferon-based therapies for multiple sclerosis","volume":"18","author":"L Dumitrescu","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"pone.0227524.ref025","article-title":"The influence of interferon on healthy and diseased skin","author":"GA Hile","year":"2018","journal-title":"Cytokine"},{"key":"pone.0227524.ref026","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fimmu.2017.00258","article-title":"Type I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology","volume":"8","author":"J Pott","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"pone.0227524.ref027","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jir.2018.0125","article-title":"Interferon Alpha 2a and 2b in Ophthalmology: A Review","volume":"39","author":"N Lewczuk","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"pone.0227524.ref028","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/OPTH.S3308","article-title":"Interferons and their potential in the treatment of ocular inflammation","volume":"3","author":"F Mackensen","year":"2009","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"pone.0227524.ref029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2013.05.002","article-title":"Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial","volume":"156","author":"F Mackensen","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"pone.0227524.ref030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1089\/jir.2014.0041","article-title":"Short Peptide type I interferon mimetics: therapeutics for experimental allergic encephalomyelitis, melanoma, and viral infections","volume":"34","author":"CM Ahmed","year":"2014","journal-title":"J Interferon Cytokine Res"},{"key":"pone.0227524.ref031","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.exer.2018.07.020","article-title":"A cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis","volume":"177","author":"CM Ahmed","year":"2018","journal-title":"Exp Eye Res"},{"issue":"2","key":"pone.0227524.ref032","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/exer.1996.0020","article-title":"ARPE-19, a human retinal pigment epithelial cell line with differentiated properties","volume":"62","author":"KC Dunn","year":"1996","journal-title":"Exp Eye Res"},{"issue":"12","key":"pone.0227524.ref033","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1167\/iovs.11-8021","article-title":"Human retinal pigment epithelium cells as functional models for the RPE in vivo","volume":"52","author":"Z Ablonczy","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"pone.0227524.ref034","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.4049\/jimmunol.178.7.4576","article-title":"IFN mimetic as a therapeutic for lethal vaccinia virus infection: possible effects on innate and adaptive immune responses","volume":"178","author":"CM Ahmed","year":"2007","journal-title":"J Immunol"},{"key":"pone.0227524.ref035","article-title":"Advances in oral peptide therapeutics","author":"DJ Drucker","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"pone.0227524.ref036","article-title":"Posttranscriptional regulation of cytokine expression","author":"P Kovarik","year":"2015","journal-title":"Cytokine"},{"issue":"7","key":"pone.0227524.ref037","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/0022034512437372","article-title":"Control of cytokine mRNA expression by RNA-binding proteins and microRNAs","volume":"91","author":"V Palanisamy","year":"2012","journal-title":"J Dent Res"},{"issue":"1","key":"pone.0227524.ref038","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2012.03.042","article-title":"Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice","volume":"143","author":"SE Lee","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0227524.ref039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1684\/ecn.2013.0334","article-title":"Contribution of TNF-alpha to the development of retinal neurodegenerative disorders","volume":"24","author":"MM Al-Gayyar","year":"2013","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"pone.0227524.ref040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/ICU.0000000000000562","article-title":"Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics","volume":"30","author":"AS Thomas","year":"2019","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"pone.0227524.ref041","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1172\/JCI33342","article-title":"The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice","volume":"118","author":"B Guo","year":"2008","journal-title":"J Clin Invest"},{"issue":"9\u201310","key":"pone.0227524.ref042","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.imbio.2008.07.022","article-title":"Interferon-alpha controls IL-17 expression in vitro and in vivo","volume":"213","author":"AR Moschen","year":"2008","journal-title":"Immunobiology"},{"issue":"2","key":"pone.0227524.ref043","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.intimp.2014.01.027","article-title":"Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2\/STAT3 pathway","volume":"19","author":"Y Xu","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"pone.0227524.ref044","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.molimm.2017.09.003","article-title":"Interleukin 17 regulates SHP-2 and IL-17RA\/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis","volume":"91","author":"R Ganesan","year":"2017","journal-title":"Mol Immunol"},{"issue":"3","key":"pone.0227524.ref045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/ICU.0000000000000466","article-title":"Cytokines in uveitis","volume":"29","author":"JE Weinstein","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"issue":"8","key":"pone.0227524.ref046","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jir.2013.0158","article-title":"How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms","volume":"34","author":"AT Reder","year":"2014","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"pone.0227524.ref047","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","article-title":"Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis","volume":"144","author":"J Plskova","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"26","key":"pone.0227524.ref048","doi-asserted-by":"crossref","first-page":"12270","DOI":"10.1073\/pnas.92.26.12270","article-title":"Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities","volume":"92","author":"PS Subramaniam","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0227524.ref049","doi-asserted-by":"crossref","first-page":"4143604","DOI":"10.1155\/2019\/4143604","article-title":"Noncanonical IFN Signaling, Steroids, and STATs: A Probable Role of V-ATPase","volume":"2019","author":"HM Johnson","year":"2019","journal-title":"Mediators Inflamm"},{"key":"pone.0227524.ref050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fimmu.2013.00202","article-title":"IFN signaling: how a non-canonical model led to the development of IFN mimetics","volume":"4","author":"HM Johnson","year":"2013","journal-title":"Front Immunol"},{"issue":"4","key":"pone.0227524.ref051","first-page":"e26227","article-title":"The role of a non-canonical JAK-STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis: An example of Occam's Broom?","volume":"2","author":"CM Ahmed","year":"2013","journal-title":"JAKSTAT"},{"issue":"8","key":"pone.0227524.ref052","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1128\/CVI.00204-14","article-title":"Type I interferon mimetics bypass vaccinia virus decoy receptor virulence factor for protection of mice against lethal infection","volume":"21","author":"CM Ahmed","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"pone.0227524.ref053","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1182\/blood-2005-07-3058","article-title":"Interferons limit inflammatory responses by induction of tristetraprolin","volume":"107","author":"I Sauer","year":"2006","journal-title":"Blood"},{"issue":"2","key":"pone.0227524.ref054","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4049\/jimmunol.174.2.953","article-title":"Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay","volume":"174","author":"RL Ogilvie","year":"2005","journal-title":"J Immunol"},{"issue":"8","key":"pone.0227524.ref055","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/jir.2010.0154","article-title":"Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3' untranslated region","volume":"31","author":"W Zhao","year":"2011","journal-title":"J Interferon Cytokine Res"},{"issue":"7","key":"pone.0227524.ref056","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.4049\/jimmunol.1300126","article-title":"Suppression of IL-12 production by tristetraprolin through blocking NF-kcyB nuclear translocation","volume":"191","author":"L Gu","year":"2013","journal-title":"J Immunol"},{"issue":"17","key":"pone.0227524.ref057","doi-asserted-by":"crossref","first-page":"11216","DOI":"10.1074\/jbc.M901229200","article-title":"Tristetraprolin mediates interferon-gamma mRNA decay","volume":"284","author":"RL Ogilvie","year":"2009","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0227524.ref058","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jir.2007.0062","article-title":"IFN-beta-mediated inhibition of IL-8 expression requires the ISGF3 components Stat1, Stat2, and IRF-9","volume":"28","author":"T Laver","year":"2008","journal-title":"J Interferon Cytokine Res"},{"key":"pone.0227524.ref059","first-page":"859145","article-title":"NLRP3 Inflammasome and MS\/EAE","volume":"2013","author":"M Inoue","year":"2013","journal-title":"Autoimmune Dis"},{"key":"pone.0227524.ref060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-319-17121-0_9","article-title":"The NLRP3 Inflammasome and its Role in Age-Related Macular Degeneration","volume":"854","author":"CJ Ildefonso","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"pone.0227524.ref061","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imr.12286","article-title":"Initiation and perpetuation of NLRP3 inflammasome activation and assembly","volume":"265","author":"EI Elliott","year":"2015","journal-title":"Immunol Rev"},{"issue":"1\u20132","key":"pone.0227524.ref062","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2010.10.018","article-title":"The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis","volume":"232","author":"LD Jager","year":"2011","journal-title":"J Neuroimmunol"},{"key":"pone.0227524.ref063","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fimmu.2015.00183","article-title":"SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function","volume":"6","author":"CM Ahmed","year":"2015","journal-title":"Front Immunol"},{"issue":"2","key":"pone.0227524.ref064","article-title":"IL-10 Modulates Th17 Pathogenicity during Autoimmune Diseases","volume":"7","author":"B Guo","year":"2016","journal-title":"J Clin Cell Immunol"},{"issue":"2","key":"pone.0227524.ref065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm1551","article-title":"A brief history of T(H)17, the first major revision in the T(H)1\/T(H)2 hypothesis of T cell-mediated tissue damage","volume":"13","author":"L Steinman","year":"2007","journal-title":"Nat Med"},{"issue":"11","key":"pone.0227524.ref066","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"H Park","year":"2005","journal-title":"Nat Immunol"},{"issue":"6","key":"pone.0227524.ref067","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/intimm\/10.6.807","article-title":"IL-10 has a protective role in experimental autoimmune uveoretinitis","volume":"10","author":"LV Rizzo","year":"1998","journal-title":"Int Immunol"},{"issue":"10","key":"pone.0227524.ref068","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/jir.2011.0042","article-title":"Cytokines in autoimmune uveitis","volume":"31","author":"R Horai","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"pone.0227524.ref069","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jaut.2013.08.003","article-title":"IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses","volume":"50","author":"WP Chong","year":"2014","journal-title":"J Autoimmun"},{"issue":"2","key":"pone.0227524.ref070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17020185","article-title":"Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos","volume":"17","author":"M Kristensen","year":"2016","journal-title":"Int J Mol Sci"},{"key":"pone.0227524.ref071","first-page":"2939370","article-title":"SOCS1 Mimetic Peptide Suppresses Chronic Intraocular Inflammatory Disease (Uveitis)","volume":"2016","author":"C He","year":"2016","journal-title":"Mediators Inflamm"},{"key":"pone.0227524.ref072","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2015.05.011","article-title":"Topical administration of a suppressor of cytokine signaling-1 (SOCS1) mimetic peptide inhibits ocular inflammation and mitigates ocular pathology during mouse uveitis","volume":"62","author":"C He","year":"2015","journal-title":"J Autoimmun"},{"key":"pone.0227524.ref073","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brainres.2015.04.035","article-title":"VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4\/NF-kappaB signaling pathway in experimental traumatic brain injury","volume":"1622","author":"W Gao","year":"2015","journal-title":"Brain Res"},{"key":"pone.0227524.ref074","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2119\/molmed.2012.00008","article-title":"Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice","volume":"18","author":"Y Liu","year":"2012","journal-title":"Mol Med"},{"key":"pone.0227524.ref075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.mcn.2015.08.001","article-title":"Eye drop delivery of pigment epithelium-derived factor-34 promotes retinal ganglion cell neuroprotection and axon regeneration","volume":"68","author":"V Vigneswara","year":"2015","journal-title":"Mol Cell Neurosci"},{"issue":"6","key":"pone.0227524.ref076","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.bbagen.2015.01.019","article-title":"Tat PTD-endostatin: A novel anti-angiogenesis protein with ocular barrier permeability via eye-drops","volume":"1850","author":"X Zhang","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"pone.0227524.ref077","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.4049\/jimmunol.0902895","article-title":"Enhancement of antiviral immunity by small molecule antagonist of suppressor of cytokine signaling","volume":"185","author":"CM Ahmed","year":"2010","journal-title":"J Immunol"},{"key":"pone.0227524.ref078","first-page":"294","article-title":"Repurposing an orally available drug for the treatment of geographic atrophy","volume":"22","author":"CM Ahmed","year":"2016","journal-title":"Mol Vis"},{"key":"pone.0227524.ref079","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.exer.2015.07.022","article-title":"Systemic treatment with a 5HT1a agonist induces anti-oxidant protection and preserves the retina from mitochondrial oxidative stress","volume":"140","author":"MR Biswal","year":"2015","journal-title":"Exp Eye Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T13:31:14Z","timestamp":1582723874000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0227524"}},"subtitle":[],"editor":[{"given":"Anand","family":"Swaroop","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":79,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0227524","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2019.12.23.886986","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]}}}